{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:31:32Z","timestamp":1786545092263,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/ajg.2011.146","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T07:59:23Z","timestamp":1304409563000},"page":"1419-1425","source":"Crossref","is-referenced-by-count":134,"title":["Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease"],"prefix":"10.14309","volume":"106","author":[{"given":"Peter J","family":"Kahrilas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesta","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210210","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus.","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R3-5-20210210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","article-title":"Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies.","volume":"32","author":"El-Serag","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-5-20210210","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.02233.x","article-title":"Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.","volume":"20","author":"Bochenek","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-5-20210210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0016-5085(92)91790-B","article-title":"Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US Multicenter Study.","volume":"102","author":"Sontag","year":"1992","journal-title":"Gastroenterology"},{"key":"R7-5-20210210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2036.1993.tb00071.x","article-title":"Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.","volume":"7","author":"Robinson","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-5-20210210","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2036.1995.tb00437.x","article-title":"Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.","volume":"9","author":"Corinaldesi","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-5-20210210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2036.2003.01464.x","article-title":"Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux oesophagitis: metropole study results.","volume":"17","author":"Lauritsen","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-5-20210210","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1001\/archinte.160.12.1810","article-title":"Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.","volume":"160","author":"Richter","year":"2000","journal-title":"Arch Intern Med"},{"key":"R11-5-20210210","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10620-005-3000-3","article-title":"Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.","volume":"50","author":"Kahrilas","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R12-5-20210210","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1572-0241.2008.02033.x","article-title":"Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: on or off proton pump inhibitor?","volume":"103","author":"Hemmink","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R13-5-20210210","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2036.2009.03948.x","article-title":"Clinical trial: the treatment of gastro-oesophageal reflux disease in primary careprospective randomized comparison of rabeprazole 20mg with esomeprazole 20 and 40mg.","volume":"29","author":"Eggleston","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-5-20210210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2036.1996.44186000.x","article-title":"Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis.","volume":"10","author":"Bate","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-5-20210210","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1046\/j.1365-2036.2000.00882.x","article-title":"Omeprazole 40mg once a day is equally effective as lansoprazole 30mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.","volume":"14","author":"Fass","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-5-20210210","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3748\/wjg.v12.i37.6017","article-title":"Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.","volume":"12","author":"Pai","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R17-5-20210210","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.3748\/wjg.v13.i30.4100","article-title":"Randomized, double-blind, comparative study of dexrabeprazole 10mg versus rabeprazole 20mg in the treatment of gastroesophageal reflux disease.","volume":"13","author":"Pai","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R18-5-20210210","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1440-1746.2005.03980.x","article-title":"Management of symptoms in step-down therapy of gastroesophageal reflux disease.","volume":"20","author":"Mine","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-5-20210210","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/003655201750313315","article-title":"High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.","volume":"36","author":"Juul-Hansen","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"R20-5-20210210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2036.1997.00185.x","article-title":"Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.","volume":"11","author":"Galmiche","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-5-20210210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.296.6615.89","article-title":"Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.","volume":"296","author":"Havelund","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R22-5-20210210","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","article-title":"Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.","volume":"4","author":"Devault","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-5-20210210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2036.1996.14156000.x","article-title":"Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.","volume":"10","author":"Gough","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-5-20210210","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(88)90162-X","article-title":"Healing and relapse of severe peptic esophagitis after treatment with omeprazole.","volume":"95","author":"Hetzel","year":"1988","journal-title":"Gastroenterology"},{"key":"R25-5-20210210","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2000.03254.x","article-title":"Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.","volume":"95","author":"Richter","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R26-5-20210210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/00365520310002157","article-title":"Symptom-relieving effect of esomeprazole 40mg daily in patients with heartburn.","volume":"38","author":"Johnsson","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"R27-5-20210210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00004836-199504000-00005","article-title":"Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study.","volume":"20","author":"Koop","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"R28-5-20210210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000051885","article-title":"Comparison of pantoprazole 20mg to ranitidine 150mg b.i.d. in the treatment of mild gastroesophageal reflux disease.","volume":"63","author":"Kaspari","year":"2001","journal-title":"Digestion"},{"key":"R29-5-20210210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.0953-0673.1996.00397.x","article-title":"Efficacy and tolerability of pantoprazole 40mg versus 80mg in patients with reflux oesophagitis.","volume":"10","author":"van Rensburg","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-5-20210210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00044011-200323020-00001","article-title":"Lansoprazole and esomeprazole in symptomatic GERD: A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief.","volume":"23","author":"Chey","year":"2003","journal-title":"Clin Drug Investig"},{"key":"R31-5-20210210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000070201","article-title":"Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.","volume":"67","author":"Korner","year":"2003","journal-title":"Digestion"},{"key":"R32-5-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2036.2004.01846.x","article-title":"Double-blind, randomized controlled study to assess the effects of lansoprazole 30mg and lansoprazole 15mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.","volume":"19","author":"Wong","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-5-20210210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2036.1995.tb00388.x","article-title":"A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial.","volume":"9","author":"Mossner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-5-20210210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.31.5.509","article-title":"Double blind comparison of omeprazole (40mg od) versus cimetidine (400mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24h pH monitoring.","volume":"31","author":"Dehn","year":"1990","journal-title":"Gut"},{"key":"R35-5-20210210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-199611000-00013","article-title":"Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group.","volume":"8","author":"Mulder","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R36-5-20210210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2036.2002.01207.x","article-title":"A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-5-20210210","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.cgh.2008.02.010","article-title":"When proton pump inhibitors fail.","volume":"6","author":"Kahrilas","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-5-20210210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gut.2007.133470","article-title":"Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.","volume":"57","author":"Zerbib","year":"2008","journal-title":"Gut"},{"key":"R40-5-20210210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1572-0241.2005.40945.x","article-title":"Assessing symptoms in gastroesophageal reflux disease: how well do clinicians assessments agree with those of their patients?","volume":"100","author":"McColl","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R41-5-20210210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1572-0241.2001.03451.x","article-title":"Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.","volume":"96","author":"Shaw","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R42-5-20210210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","article-title":"A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.","volume":"103","author":"Dent","year":"2008","journal-title":"Am J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2011146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011146","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201108000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:36:10Z","timestamp":1786541770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201108000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.146","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}